Safety Reading Notes

Read safety context beside the research guide.

The CB1 receptor neurobehavioral/metabolic source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 30767756

PubMed For Dummies Article

CB1 receptor neurobehavioral/metabolic Evidence Review: the long-form source walk-through

Quick read
  • CB1 receptor neurobehavioral/metabolic currently has 24 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 30767756
  • The evidence classes most visible in the row language are insufficient (14), and mechanistic or pharmacological (10). PMID 28527758
  • The study-design language most visible in the row language is Narrative or expert review (13), Animal study (9), Meta-analysis or systematic evidence synthesis (1), and other mapped categories (1). PMID 20590557
  • The repeated topics are CB1 (24), which tells the reader where to start opening PubMed and DOI links. PMID 34050525

Start with the research question

CB1 receptor neurobehavioral/metabolic is built from 24 source-backed evidence row(s) and 24 research source(s). The current evidence classes read as insufficient (14), and mechanistic or pharmacological (10), and the study-design language most often reads as Narrative or expert review (13), Animal study (9), Meta-analysis or systematic evidence synthesis (1), and other mapped categories (1). PMID 30767756

The row-level question is not simply whether CB1 receptor neurobehavioral/metabolic is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are CB1 (24). PMID 17895407

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 27086601

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 17895407

Mechanistic evidence 10 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 31771126

Limits and uncertainty 14 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 16570099

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 19939187

Where this page has the most source density

The largest bucket surfaced for this page is CB1: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB1: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 30767756

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 17895407

Bucket chapters: what the literature is circling

CB1: insufficient

14 research sources 14 rows (839-862) Evidence class: insufficient

This bucket summarizes source-backed rows focused on CB1: insufficient. It currently draws from 14 research source(s), so the exact study type matters. PMID 30767756

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 30767756

  • Evidence row 839

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 30767756

  • Evidence row 862

    Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or... PMID 16596773

CB1: mechanistic or pharmacological

10 research sources 10 rows (844-861) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on CB1: mechanistic or pharmacological. It currently draws from 10 research source(s), so the exact study type matters. PMID 17895407

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 17895407

  • Evidence row 844

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or... PMID 17895407

  • Evidence row 861

    Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metaboli... PMID 36613469

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (10 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 30767756

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 17895407

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 19285266
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 31461639
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 15550444

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 30767756

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 17895407

Source-reading checklist for CB1 receptor neurobehavioral/metabolic

  1. Open the linked PubMed or DOI record. PMID 36088492
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 35429587
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 40855505
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 31491589
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 25967266

Source Notes

CB1 receptor neurobehavioral/metabolic source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 839

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 30767756

    Evidence class: insufficient; Study design: Narrative or expert review. Source: New Insights in Cannabinoid Receptor Structure and Signaling.
  2. Evidence row 840

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 28527758

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.
  3. Evidence row 841

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 20590557

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?
  4. Evidence row 842

    Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 34050525

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.
  5. Evidence row 843

    THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 27086601

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid System: A Multi-Facet Therapeutic Target.
  6. Evidence row 844

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 17895407

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a.
  7. Evidence row 845

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31771126

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities.
  8. Evidence row 846

    Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 16570099

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The pharmacology of cannabinoid receptors and their ligands: an overview.
  9. Evidence row 847

    Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 19939187

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Latest advances in cannabinoid receptor agonists.
  10. Evidence row 848

    THC modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 19285266

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
  11. Evidence row 849

    Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31461639

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.
  12. Evidence row 850

    Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 15550444

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The endocannabinoid system: physiology and pharmacology.
  13. Evidence row 851

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 36088492

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Peripheral CB1 receptor blockade acts as a memory enhancer through a noradrenergic mechanism.
  14. Evidence row 852

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 35429587

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Role of the cannabinoid CB1 receptor in methamphetamine-induced social and recognition memory impairment.
  15. Evidence row 853

    Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 40855505

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models.
  16. Evidence row 854

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31491589

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Adipocyte cannabinoid CB1 receptor deficiency alleviates high fat diet-induced memory deficit, depressive-like behavior, neuroinflammation and impairment in adult neurogenesis.
  17. Evidence row 855

    Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 25967266

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.
  18. Evidence row 856

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 27828947

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A cannabinoid link between mitochondria and memory.
  19. Evidence row 857

    Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 39300547

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome.
  20. Evidence row 858

    THC modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31165913

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species.
  21. Evidence row 859

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 35595026

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Cross state-dependent memory retrieval between cannabinoid CB1 and serotonergic 5-HT1A receptor agonists in the mouse dorsal hippocampus.
  22. Evidence row 860

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 38482984

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Adenosine receptors are the on-and-off switch of astrocytic cannabinoid type 1 (CB1) receptor effect upon synaptic plasticity in the medial prefrontal cortex.
  23. Evidence row 861

    Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 36613469

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice.
  24. Evidence row 862

    Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 16596773

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice.